Objective To analyse the cost-effectiveness (C-E) of interferon therapy for MS and the impact of adherence associated with a patient support programme (PSP). Methods Markov model was structured based on systematic review of the evidence and the opinion of local experts. The model has three health states: (1) Baseline treatment (BT), (2) Interferon-b (IFN) with patient support programme (PSP) and (3) Conclusion The addition of a PSP had a significant effect on adherence and C-E of the intervention. The ICER for IFN + PSP was below 1.5 annual GDP-pc of payment threshold with an incremental cost near to 3 GDP-pc. IFN without PSP was dominated by the IFN + PSP.
Introduction
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is characterized by episodes of neurological symptoms (called relapses) and progressive disability. [1] The aetiology of MS is unknown, but there are several hypotheses that account for epidemiological and environmental factors, such as infections and genetics. [2] A recent systematic review published in 2017 estimates the epidemiological characteristics of MS in Latin America, based on the results available from seven countries. [3] This study shows that the incidence of MS in Latin America fluctuates in the range of 0.15 to 3 annual cases per 100 000 person-years. [3] Likewise, the estimated prevalence was in the range from 0.75 to 38.2 cases per 100 000 person-years. [3] The only study in Peru estimating the prevalence of MS shows that it is 7.69 cases per 100 000 inhabitants with a range from 7.09 to 8.30 (95% confidence interval), classifying Peru as a country with mediummoderate level of prevalence. [4, 5] With regard to the natural history of the disease, relapses are the most frequent clinical feature of MS. These are recognized by their symptomatology according to their anatomical locations. The vast majority of patients experience an initial phase of relapse-remission. Additionally, more than 80% of patients will develop secondary progression of disability with or without overlapping relapses. [6] The course of the disease is variable, most frequently progressing through numerous phases of relapse-remission, including ocular symptoms and usually a better prognosis. The second most frequent form is primary progressive, with cerebellar motor involvement and worse prognosis. These are followed by: secondary progressive, progressive relapsing and, controversially, the clinically isolated syndrome (CIS). [5] The role of auxiliary imaging tools such as magnetic resonance imaging (MRI) is fundamental for diagnosis, since the diagnosis may be clinical with MRI or at times may rely only on MRI findings. [2] In the past 20 years, treatment for MS has been developed using drugs whose mechanism of action suppresses or modulates the immune response, termed disease-modifying therapies (DMTs). This type of treatment affects the course of the disease by suppressing the autoimmune response. [7] DMTs have shown favourable results mainly in relapsing-remitting MS, so they are often recommended in this case. [8] Treatment with DMTs aims to reduce the frequency of relapses, as well as to slow down the progression of the disease and disability. [7, 8] There are different cost-effectiveness studies of these drugs, but because costs vary by country and Peru is considered a medium-prevalence country of MS, a cost-effectiveness study is needed to determine which treatment would benefit the quality of life of the patient in a cost-efficient manner.
The present economic evaluation aims to evaluate the cost-effectiveness (C-E) of three treatment strategies for managing MS available in Peru, using local prices.
Method
A local C-E analysis was developed comparing three firstline treatments for MS: (1) Baseline treatment (BT), (2) Interferon-b (IFN) with patient support programme (PSP), and (3) IFN without PSP.
For this, a Markov model was structured based on the systematic review of the evidence and the opinion of local experts. The economic model is composed of four health states, delineated in Figure 1 .
At the end of each Markov cycle, the patients remain or advance to a more severe state. Annual cycles were considered, with a time horizon of 30 years (considering the mean survival of the disease). The analysis perspective was based on the Ministry of Health (MoH).
According to previous studies, [6, 9, 10] the transition probabilities were estimated to predict outcomes of disease progression, death or treatment effectiveness. In addition, the analysis incorporated probabilities of adherence to the IFN treatment, when combined with a PSP, that were extrapolated from the literature (Table 1) . [11] [12] [13] [14] The following network meta-analyses were used to incorporate efficacy data into the model: Tolley et al. [15] (2015), Tramacere et al. [16] (2015) and Fogarty et al. [17] (2016), as well as available head-to-head comparative clinical trials.
The cost matrix was prepared in accordance with the opinion of local experts and the clinical practice guidelines of two reference MoH hospitals (National Institute of Neurological Sciences, INCN and Arzobispo Loayza National Hospital, HNAL). All the monetary units of the study are expressed in Soles from the year 2017. A discount rate of 5% was applied for both costs and profits. Although local cost data were used, the data for Quality Adjusted Life Year (QALY) were extracted from international published literature. [1, 17] In addition, the following assumptions were considered as follows: 4 The hypothetical cohort begins at age 30-40 (mean age of incidence). 5 The composition of the BT is given by all support and treatment measures currently applicable in our environment and in real conditions after the diagnosis of the disease (symptomatic, corticosteroid therapy, DMTs provided temporarily [average 1 year], etc.). 6 Mortality from MS was assumed according to published local evidence. The survival at 10, 15, 20 and 25 years was 87%, 82%, 76% and 45% respectively. [5] Survival was significantly less than reported by others. [18, 19] The clinical form was not relevant for mortality. [5] 7 For CIS state, a general mortality rate was adopted for the adult population between 30 and 60 years old (according to data from the National Institute of Statistics and Informatics (INEI)), considering the age of highest incidence of disease. [20] Likewise, all patients at CIS state in the IFN arms of the model received at least 2 years of the corresponding treatment. 8 According to local experts and previous publications, the following distribution of the Expanded Disability Status Scale (EDSS) was assumed in the cohort for state utility estimation: 46% of patients had EDSS < 5, 36% had EDSS between 5% and 8%, and 18% had EDSS > 8. [5, 21] 9 RRMS and PMS states accumulate yearly the same average utility (0.745 QALY), as long as they do not relapse. So, in case of a disease relapse, the disutility for Figure 1 Markov health states. the RRMS state was considered À0.094, and the disutility for the PMS status was considered À0.255. [22] For the evaluation of results, the increments for cost and effectiveness were estimated for the two alternatives, which allowed the cost per QALY or ICER (incremental costeffectiveness ratio) to be known for each of them. Probability sensitivity tests were performed. TreeAge Pro software (Williamstown, MA, USA), Healthcare module, v.2018 was used for the analysis.
Extended analysis of budgetary impact
By means of first-order microsimulation of the decision tree, we proceeded to analyse the simulation of a cohort of 150 patients (estimate of the total of patients with MS attended in MoH subsector) to estimate some additional impact results, such as the incremental number of relapses and health state 'switches', taking into account that these measures of effectiveness are indirectly related to the QALY effectiveness outcome.
Results
Cost-effectiveness analysis of the model The deterministic analysis (Table 2 and Figure 2) shows that the IFN + PSP option dominates the IFN without PSP treatment, and is more effective and costly than BT. However, only the IFN + PSP option is below a payment threshold equivalent to 1.5 times the annual GDP-pc (approximately S/. 30 000 in Peru). The ICER for the IFN + PSP treatment was estimated at S/. 26 408 per QALY in relation to the BT (1.3 times the annual GDP-pc) with an incremental cost of S/. 67 894. The IFN without PSP treatment showed an ICER of S/. 195 406 with respect to the BT and was dominated by the IFN + PSP treatment (i.e. it was less effective and more expensive). Figure 3 illustrates the probabilistic distribution of these results. Figure 4 shows the probabilistic cloud of dots of the ICER corresponding to the comparison of the IFN + PSP treatment versus the BT. In the figure, 99% of the dots are below a payment threshold of 3 annual GDP-pc (60 000 Soles for Peruvian case).
In close relation to the previously observed, Figure 5 illustrates the acceptability curves that are generated with 1000 probabilistic simulations of the model (Monte Carlo simulations) against a range of thresholds defined between S/. 0 and S/. 60 000 (3 times the GDP-pc). The 'y' axis corresponds to the proportion of simulations (iterations). It is observed that the IFN + PSP treatment is probabilistically more cost effective from a payment threshold equivalent to 1.25 times the annual GDP-pc (S/. 20 000). It is also observed that IFN without PSP is dominated. Finally, the Tornado analysis for ICER between IFN + PSP and BT (i.e. excluding the dominated treatment) illustrates that the most sensitive variables to modify the model results are the RR for treatment adherence and the cost of the intervention with IFN + PSP ( Figure 6 ). However, the maximum limits considered for these variables do not increase the ICER beyond 3 times the GDP-pc.
Extended analysis of budget impact
By means of a microsimulation of the economic model, we proceeded to analyse the simulation of a cohort of 150 patients, which would be the estimated number of patients in Peru (despite the fact that Peru still does not have reliable statistics regarding incidence and prevalence). The simulation allowed to calculate an average cost of S/. 29 194 564 and S/. 42 325 844 for BT and IFN + PSP, respectively (45% increase with the IFN treatment). In the same sense, both options accumulated 524 and 912 QALYs respectively. So, the ICER was equivalent to 1.6 annual GDP-pc. The model simulation on this cohort estimated a total number of 230 'avoided relapses', 25 'avoided RRMS?PMS switches', 10 'avoided CIS?RRMS switches' and 5 'avoided deaths' with the option IFN + PSP (Table 3) .
Discussion
Referring to the baseline scenario, treatment with IFN + PSP was more efficient than IFN without PSP, with a cost/QALY within 1.5 times the annual GDP-pc (with an incremental cost near to 3 GDP-pc).
Although the ICER for most treatments that incorporate DMTs often exceeds the threshold of the annual GDP-pc in the local context, it is important to emphasize the need for a national consensus on an appropriate cost threshold. This is because some diseases (such as MS) would require a greater availability of funds for treatment because they are conditions of very low prevalence, but with a high burden of morbidity and mortality. MS affects young adults (30-40 years of age) disproportionately and can cause progressive mid-to-long term disability if there is not early, adequate and sustainable intervention. In Peru, there are no official data on the prevalence of MS, but some reports estimate that the total number of diagnosed patients could be around 400 patients. Even so, this is a figure that could be biased downward due to underreporting. Currently, there is a trend to generalize the availability of funds for treatment by decision-makers to a maximum threshold ranging from 0.5 to 1.0 times the annual GDP-pc, considering that this threshold would be a direct function of health expenditure per capita (HE-pc) and life expectancy (LE) in the local context. This recommendation has been revised recently and would be better adjusted for a local context, compared with the traditional WHO recommendation of considering 1-3 times the GDP-pc as a general payment threshold. However, this adjustment responds to the need to contextualize the threshold to the regional political-economy scenario, but specifically excludes diseases with very low prevalence, especially those that tend towards chronicity or diseases that significantly impact life expectancy. In this regard, there is still no validated method to estimate the ideal payment threshold for these types of conditions. However, by adopting the same estimation model, it could be assumed that the threshold for such diseases could be near 3 times the GDP-pc. These estimates provide sufficient justification for further pharmacoeconomic evaluation of MS.
On the other hand, the positive impact of patient support programs (PSP) as a key element to support the therapeutic response in many chronic diseases is very clear. This is because the patient usually interrupts the intervention for various reasons, such as having a concomitant depressive disorder, or an onset of any adverse effect that does not necessarily justify treatment withdrawal. Moreover, apparent stability of the disease or even social or family circumstances may cause patient attrition from treatment. Some studies have evaluated this issue with the use of IFN in multiple sclerosis. Hupperts et al. [13] studied the effect of adherence to treatment on disease activity, measured as the annual relapse rate, finding that the proportion of relapse-free patients in subgroups with good/ very good adherence and poor/very poor adherence was of 77.6% and 50%, respectively (annual relapse rate: 0.3 and 0.9, respectively). Franklin et al. [14] estimated an OR (odds ratio) of 2.35 (CI95: 2.01-2.74) to support IFN therapy when an appropriate PSP was incorporated into the first year of treatment. More recently, Bayas et al. [12] determined a level of adherence of 97.1% per year of IFN treatment, where 79.5% of patients remained relapse-free. The annual relapse rate was reduced from 1.9 to 0.3 over 1 year of follow-up. According to studies evaluating adherence with the use of IFN, the three most frequent reasons for withdrawal are as follows: forgetting the injection (37%), reluctance to injection (19%) and 'discouragement' to continue injections (10%). This contrasts with those reasons that could be assumed to be more important, such as: onset of flu-like symptoms or pain at the injection site. Accordingly, the estimated withdrawal rate due to adverse effects approaches 5% and, therefore, the occurrence of an adverse effect would not generally justify discontinuation of IFN, therapy.
Regarding the BT, it should be noted that this option refers to the most generalized intervention for those patients who are diagnosed with MS. The BT refers to the best support treatment that is currently done to deal with this disease. That is, it answers the question 'what is currently being done for these patients?' Then, the resulting costeffectiveness question is 'what options are more cost effective versus what is currently done?' According to local data, patients with MS often receive symptomatic support and corticosteroids for relapses. And in inter-relapse stages, they receive physical rehabilitation and some DMT, for an average time of 1-2 years, which is interrupted in the great majority of cases due to lack of adherence or difficulty in access to medication. In this scenario, our analysis compares the interventions considered as first-line: BT and IFN. However, given the lack of adherence as a critical factor of the therapeutic response, the alternative options were defined as: IFN with PSP (IFN + PSP) and IFN without PSP, because in Peru, sometimes PSP accompanies IFN treatments (expert opinion).
We must recognize some limitations for the present model: (1) the model extrapolates some transition probabilities and data for QALY and adherence from published studies because there are no reliable local data, and (2) the efficacy data are extrapolated from network meta-analyses. Although this type of meta-analysis evaluates mixed comparisons (combination of indirect and direct results) and the level of inconsistency of the study network, the robustness of its final result could be weakened by the number of indirect comparisons across studies in the network. Thus, future head-to-head trials would consolidate and likely increase the precision of the consensus on the estimated magnitude of the effect derived from literature.
Similarly, we must highlight some strengths: (1) the cost matrix was structured based on two sets of local clinical guidelines, which were validated by local experts, (2) costs were extracted from local hospital price-lists and also included some indirect costs such as loss of employment because of disability and physical rehabilitation.
Finally, the budget impact analysis (for an estimated cohort of 150 patients) estimated a total number of 230 avoided relapses, 25 avoided 'switches from RRMS? PMS', 10 avoided 'Switches from CIS?RRMS' and 5 avoided deaths with the option IFN + PSP.
As mentioned above, the payment threshold comes from a theoretical model defined as a function of only two key variables: HE-pc and LE, expressing the former as monetary units and the last one as QALYs (or DALYs). That is, the standard payment threshold does not consider any outcome of effectiveness other than QALY (or DALY). Therefore, alternative outcomes like 'cost per avoided relapse' or 'cost per avoided switch' cannot be analysed in relation to its equivalence in GDP-pc because they are not directly incorporated in the payment threshold function. In our model, the sum of these "non-QALY" results was considered as 'total negative events avoided', yielding a total of 270 negative events avoided for the option IFN + PSP.
Conclusion
The addition of a PSP has a significant effect on the adherence and cost-effectiveness of the MS intervention in Peru. The cost/QALY for treatment with IFN + PSP is below a payment threshold of 30 000 Soles (1.5 times the GDP-pc in Peru). Other outcomes of clinical relevance such as "avoided relapses", "avoided switches from RRMS to PMS" or "avoided switches from CIS to RRMS", showed a favorable trend towards treatment with IFN + PSP when contrasted with BT.
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